Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells.
FR901228, a novel antitumor antibiotic, reversed the transformed morphology of the Ha-ras transformants, Ras-1 cells, and inhibited their growth. The reduction of c-myc expression was observed in FR901228-treated Ras-1 cells by RNA dot-blot hybridization. This reduction of c-myc expression and morphological reversion of the transformed cells to normal were correlated with growth inhibition (G0/G1 arrest in cell cycle).
Ueda
H
H
Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Ibaraki, Japan.
Nakajima
H
H
Hori
Y
Y
Goto
T
T
Okuhara
M
M
D016475:3T3 Cells / Q000187:drug effects / Q000502:physiology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D015152:Blotting, Northern; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002461:Cell Line, Transformed; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D002861:Chromobacterium / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D047630:Depsipeptides; D005434:Flow Cytometry; D015870:Gene Expression / Q000187:drug effects; D016259:Genes, myc / Q000187:drug effects; D011905:Genes, ras / Q000187:drug effects*; D007700:Kinetics; D046911:Macromolecular Substances; D051379:Mice; D010456:Peptides, Cyclic; D015398:Signal Transduction / Q000187:drug effects; D014162:Transfection; D014170:Transformation, Genetic / Q000187:drug effects*; D001749:Urinary Bladder Neoplasms / Q000235:genetics
D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D004273:DNA, Neoplasm; D047630:Depsipeptides; D046911:Macromolecular Substances; D010456:Peptides, Cyclic; C087123:romidepsin